Conjugation | Definition of Conjugation by Oxford

conjugation chemistry meaning

conjugation chemistry meaning - win

What does “Stable” mean when talking about a “stable conjugate base” in acid-base chemistry?

Edit: Thanks to everyone who answered!
submitted by jehkahb to chemhelp [link] [comments]

[College 1st Year, Intro to Chemistry] I have already discarded the first and last combination, but I'm not sure if it's none of them or the second one. Can potassium butanoate be the conjugate base of butanoic acid? And does the pka of butanoic acid of 4.82 mean that it wouldn't be a good buffer?

[College 1st Year, Intro to Chemistry] I have already discarded the first and last combination, but I'm not sure if it's none of them or the second one. Can potassium butanoate be the conjugate base of butanoic acid? And does the pka of butanoic acid of 4.82 mean that it wouldn't be a good buffer? submitted by AmeliaCunningham to HomeworkHelp [link] [comments]

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
I posted this on pennystocks yesterday.
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the Orphan Drug Act, there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.
All-Star Management Team
CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through Inabata & Co. Ltd, a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).
Robust Drug Pipeline
Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).
Huge Upcoming Announcements
The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.
Downsides
Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.
------------------------------------------------------------
TL;DR.
Resources
Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to TheDailyDD [link] [comments]

Vaccines On Demand, with Engineered Cells (+All the synthetic biology research this week)

On-Demand Vaccines for Bacterial Infections: A new study, published in Science Advances, describes a method to produce conjugate vaccines—which are used to prevent some of the leading causes of vaccine-preventable deaths, according to the World Health Organization—using ground up, freeze-dried bacteria. E. coli bacteria were first engineered to produce an antigen for a pathogenic microbe of choice. Then, the researchers ripped open the cells and added in a piece of DNA encoding a carrier protein, which attaches to those antigens and helps display them to the immune system. The team turned the whole mixture into a powder that could be transported and stored at room temperature. Then, to make a dose of vaccine, they just add water. The freeze-dried tube produces the vaccine, on demand, in about one hour. As a proof of concept, the researchers manufactured vaccines that protected mice against a disease-causing bacteria, Francisella tularensis. The work was authored by researchers at Northwestern University in Evanston, Illinois.
Why It Matters: Most vaccines need to be stored at cold temperatures. This makes it difficult to transport them to parts of the world without a temperature-controlled supply chain. This study could help make vaccines accessible to a greater number of people. The technique is also very general; it can be used to make just about any conjugate vaccine that is on the market today. Conjugate vaccines are already used to prevent a lot of childhood diseases, including multiple types of bacterial meningitis, which killed an estimated 300,000 people in 2016. That’s according to a 2018 study30387-9/fulltext) in The Lancet Neurology.
Cas13a Treats SARS-CoV-2 and Flu: DNA targeting CRISPR enzymes, including Cas9 and Cas12a, can manipulate genomes with ease. But there are also CRISPR proteins that target RNA, including the Cas13 ‘family.’ Since influenza and SARS-CoV-2 are both RNA-based viruses, Cas13 can be used to target, and chop up, their genetic material. For a new study, published in Nature Biotechnology, researchers at the Georgia Institute of Technology and Emory University, in Atlanta, used Cas13a to cut specific regions of the influenza and SARS-CoV-2 viruses. They first searched for guide RNAs that could cut these viruses in a cell culture model. Then, they packaged up an mRNA sequence encoding Cas13a, together with its ‘guides,’ and delivered them into mouse airways with a nebulizer (a device that converts liquid into a fine mist). In the mice, “Cas13a degraded influenza RNA in lung tissue efficiently when delivered after infection, whereas in hamsters, Cas13a delivery reduced SARS-CoV-2 replication and reduced symptoms.”
Why It Matters: Vaccines are great for fending off diseases. But knocking out a respiratory infection—after it has already happened—is much more challenging. This study shows that a CRISPR-based system can be programmed to target viruses, and can be easily delivered into airways with a nebulizer. This approach could likely be used to target other types of respiratory infections in the future.
Glucose Sensor Upgrade: For a new study, published in Nature Communications, researchers at the University of Toronto merged engineered cells with a standard glucose meter, expanding the number of molecules that can be measured with these common devices. Glucose test strips are typically coated with an enzyme, called glucose oxidase, that senses sugar and converts that signal into electricity. The researchers built a genetic circuit that can sense a wider array of molecules—like an antigen from a pathogenic microbe—and produce a commensurate amount of sugar. Standard glucose test strips can then be used to measure the concentration of those ‘sensed’ molecules in about an hour. The genetic circuit + glucose sensor combo was used to measure small molecules and synthetic RNAs, including “RNA sequences for typhoid, paratyphoid A and B, and related drug resistance genes” at attomolar concentrations.
Why It Matters: The ongoing pandemic has highlighted the need for scalable, rapid testing. By leveraging a household technology—glucose sensors—to detect a wider range of molecules, perhaps this study could be an entryway for synthetic biology; a way to get engineered cells into the hands of more people.
Open the Genetic Floodgates: There are many ways to “turn on” a single gene, but few options to do the same for many genes at once. The Cas12a protein, though, is uniquely suited to this purpose. For a new preprint, which was posted to bioRxiv and has not been peer-reviewed, researchers at the University of Edinburgh used a Cas12a protein from the bacterium, Francisella novicida, to activate six genetic targets at once. They encoded six crRNAs—nucleotide sequences that direct Cas12a to a genetic target—in a single piece of DNA, and swapped around their order to study how their position impacts the efficiency of gene editing. They found that the crRNA in the last position was produced in the lowest amount.
Why It Matters: Researchers have been activating specific genes in cells for decades. But only recently—in the last few years—has ‘multiplexed’ activation become simple; routine even. This new preprint is important, in my opinion, because of the depth of its experiments. The team played with the order of crRNAs, as I’ve already written, but they also tested the synergism of crRNAs. In other words, can you turn a gene on at even higher levels if you target it with two crRNAs instead of one? (Yes.)
CRISPR Clocks: The Cas9 protein cuts DNA at a steady pace. Cut…cut…cut, like a wobbly metronome. For a new study00014-3), published in Cell, researchers at the Yonsei University College of Medicine, in Seoul, Korea, used this “CRISPR clock” to record the timing of cellular events. They figured out how long it takes Cas9 to cut DNA (every DNA sequence takes a different amount of time to cut) and then sequenced the DNA to figure out the amount of time that had elapsed. The “clocks” were tested in HEK293T, a type of human liver cell, and also in mice. The clocks could be turned “on” by inflammation or heat. In one experiment, the researchers put cells with these clocks into mice, and then injected the animals with fat molecules that cause inflammation. They sequenced the cells, and found that they could determine the elapsed time, from genetic sequencing alone, with a mean error of just 7.6 percent.
Why It Matters: Biological clocks are useful for many reasons. The researchers said that their CRISPR clocks could be used to record when a pre-cancerous cell is turned into a cancer cell, for example. Scientists could expose cells to toxins, for example, and then measure the amount of time that it takes for cancerous growth to begin. The CRISPR clocks could be used to study these effects inside of living cells.
More Studies

Special Issue: 20 Years of the Human Genome

Biosensors

Fundamental Discoveries

Genetic Circuits

Genetic Engineering & Control

Medicine and Diagnostics

Metabolic Engineering

New Technology

Protein Engineering

Systems Biology and Modelling

submitted by Mailyk to biotech [link] [comments]

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the [Orphan Drug Act](https://www.wikiwand.com/en/Orphan_Drug_Act_of_1983#:~:text=The Orphan Drug Act of,residing in the United States.)), there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.

All-Star Management Team

CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through [Inabata & Co. Ltd's](https://www.wikiwand.com/en/Inabata_%26_Co.,_Ltd.)), a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).

Robust Drug Pipeline

Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).

Huge Upcoming Announcements

The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:

  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.

Downsides

Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.

------------------------------------------------------------
TL;DR.

Resources

Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to pennystocks [link] [comments]

Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]
Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.
I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.
With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑
Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.
This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.
$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.
Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the [Orphan Drug Act](https://www.wikiwand.com/en/Orphan_Drug_Act_of_1983#:~:text=The Orphan Drug Act of,residing in the United States.)), there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.
So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.
Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.
Let's dive deeper into this hidden gem.
All-Star Management Team
CEO Paul Michaels
Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through [Inabata & Co. Ltd's](https://www.wikiwand.com/en/Inabata_%26_Co.,_Ltd.)), a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.
In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.
VP Communications Pam Bisikirski
Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.
Scientific Advisory Board
Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.
Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.
Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).
Robust Drug Pipeline
Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.
1) IMT504 immune therapy to treat late-stage rabies.
(11/23/2020 Announcement implies IMT504 rabies license deal is complete)
Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year).
Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.
2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.
(10/16/2020 NIH gives a grant of license for worldwide rights)
The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.
3) Metformin repurposed to treat retinal degeneration.
(2/4/2021 NIH gives a grant of license for worldwide rights)
This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).
Huge Upcoming Announcements
The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.
Downsides
Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.
Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.
Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.
Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.
Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.
------------------------------------------------------------
TL;DR.
Resources
Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.
Company
Company Website (new website coming soon w/ new company name)
Yahoo Finance (has all their press releases, financial summaries, and prospectives)
"Prospective" Grant Listings (all grants listed have been approved)
CTYX Financial Filings
CTYX Share Structure and Security Details
Insider Personel
CEO LinkedIn (Paul M Michaels)
CSO LinkedIn (Barry A. Ginsberg)
VP Communications (Pam Bisikirski)
Chairman of Audit Committee of Board (Michael K. Fish)
Forums / Discussions
https://stocktwits.com/symbol/CTYX (~200 followers right now)
https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)
submitted by charzhar to investing [link] [comments]

Acids and bases

[https://pubchem.ncbi.nlm.nih.gov/periodic-table/png/Periodic_Table_of_Elements_w_Chemical_Group_Block_PubChem.png ] or [https://ptable.com/#Properties ]
If we are going off the Lewis definition of acids as electron pair acceptors and bases as electron pair donors, the problems of ion solubility (mostly H+ and OH- ions) can be appropriately distanced from the actual behavior of hydronium (H3O+) or hydroxide (OH-) complexes in water. In other words, we first ask what species exist in what concentrations in the solution of interest, then what will happen between the different species. However, we cannot completely separate the Brønsted-Lowry and Lewis definitions due to Le Chatelier’s principle, which would state that the presence of the products of dissociation tend to prevent additional dissociation events. However, if product ions start being consumed in other reactions, the effective result is to shift the equilibrium back towards the starting materials, and additional dissociation events will then become energetically favorable. The result of this is that the behavior of chemical reactions is best contemplated holistically and with a full set of executive functionality instead of being taught as a series of disconnected fragments that imply the existence of a much higher level of precision than is actually ever possible and must be stitched together by students working without the benefit of fully developed brains. As I go through the process of writing out this series of posts, I am getting the definite impression that the progress that has been made in our understanding of atoms and orbitals has mostly obsoleted the way that general chemistry is currently taught, and that the current state of teaching is centered around exams to the detriment of the students. My general chemistry education also had far too much emphasis on the Brønsted-Lowry definition of acids and bases instead of treating these as equilibrium problems.
So and before we go any farther, let’s get pH out of the way. A lowercase “p” denotes the mathematical operation of taking the negative log of a quantity for some reason, so pH is actually the negative (base 10) log of H where H is the ionic activity of “H+” in the solution of interest. As it turns out, this is actually the activity of hydronium complexes instead of lone protons, but unless you are trying to visualize what is actually happening in the solution the two can be treated as equivalent. Of course, if you’ve gotten so obsessed with applying equations to chemical processes that you are willing to ignore the three-dimensional picture, you’re probably also not doing anything of value, but anyway. In most cases, pH can be calculated with the concentration of hydronium in moles per liter instead of a more rigorous activity measurement, so in other words pH is mostly equal to -log([H3O+]). [I should also note that the difference between the concentration of hydronium and the concentration of protons is not particularly significant in acid-base problems because the protons in water will either react with other species or form hydronium. If you are calculating the concentration of protons in water at any given time, you are also calculating the concentration of hydronium.] If you’re willing to get pedantic there is a nearly infinite amount of additional complexity that can be brought in here, but I’m not emotionally invested in this and see no reason to care. Proceeding with pH=-([H3O+]), you may notice that we are only calculating the acidity of our solution and not the basicity.
However, due to the spontaneous dissociation/autoionization of water, acidity and basicity are closely related to each other. In a volume of water, the multiplication product of the concentrations in moles per liter of hydronium/H3O+ and hydroxide/OH- is a constant. At 25 degrees Celsius, this constant (Kw) is equal to 1.0x10^-14, and Kw=[H3O+]*[OH-]. In this notation scheme, the square brackets denote concentration in moles per liter, and square brackets are usually but not always moles per liter. In any case, the reason to care is that the assumptions here mostly hold true once we start adding additional chemical species to the volume of water we started with. As the number of ions in solution increase, other issues start to arise, but mostly what you need to remember is that this is a simplified model and not an absolute definition of what is happening on the molecular level. Where this model is valuable is in relating the concentration of hydronium to the concentration of hydroxide (both in moles per liter) in a mostly reliable manner, which means that if we know a value for one at a given time we can calculate the value of the other one. So, if you have a concentration of hydroxide and you want to know the pH, you can use Kw to calculate the concentration of hydronium, then take the negative base 10 log of the result to get to pH. The addition of the logarithm allows the comparison of numbers with vastly different orders of magnitude but also brings quite a bit of confusion. In any case, using these assumptions we can define interrelated pH and pOH scales to measure acidity and basicity as the density of hydronium and hydroxide in solution. You may notice that this aligns well with the Lewis definitions, although we are not considering any other possible Lewis acids or bases.
Once you get into organic chemistry and start trying to do reactions, having a trace amount of ions in your reaction mixture doesn’t get you anywhere, and all of the assumptions as previously defined get thrown out of the window. At high concentrations of ions/high ionic activities (which are mostly equivalent concepts), we get back to the idiosyncratic and non-intuitive behavior that we expect to see in chemistry. These conditions also favor the Lewis definitions, and if it seems like I am being a bit heavy-handed in mentioning the advantages of teaching the Lewis definitions to students as early as possible you would be quite correct. Fully embracing the Lewis definitions will require the more neurotic or tradition-bound individuals among the chemical community to let go of literally centuries of work that turns out not to be valid, but as before I have no particular emotional investment in Brønsted-Lowry and would much prefer to be taught the concepts in a way that actually makes sense.
In my list of topics I am supposed to cover acid-base equilibrium, which in the context of water (aqueous solutions) is how hydronium and hydroxide move into and out of solution. First looking at “HA” or a proton donor, we can either have the acidic proton attached to the conjugate base or not. The Lewis basic strength of “A-” determines how tightly the H+ is bonded and therefore how accessible it is to the surrounding water molecules. If the H+ is bonded too tightly, there is no chance of a water molecule ever removing it, and the compound is probably not going to be participating in any aqueous acid-base reactions. At this point I am really wanting to bring in some more organic chemistry concepts and talk about an example like ethanol (CH3CH2OH) as a compound with three distinct types of protons in three different chemical environments, with the hydrogen on the oxygen end (Eth-OH) as well as the two lone pairs on the oxygen being the most interesting electron pair acceptors and donors, but the current general chemistry syllabus as defined by the American Chemical Society (ACS) prevents this. Moving on to “BOH” in water, the strength of the bond between “B+” and hydroxide is also going to be important. As an example, the hydroxl group on ethanol has essentially no chance of being removed in an aqueous solution unless something quite energetic/violent happens, but the hydroxl proton can be stripped off or another proton can bond to one of the lone pairs on oxygen depending on the reaction conditions.
In the context of this post, I am basically trying to get into a decent position to talk about buffers. These are modeled by the Henderson Hasselbalch equation and are usually a combination of a weakly proton-donating “HA” with the “A-” part of that molecule paired with a positively charged counterion (counter-cation possibly). As an example cation, let’s choose sodium (Na+), which is a terrible electron pair acceptor because it is already in a noble gas valence electron configuration and adding electrons will be destabilizing. So, we can basically ignore the sodium ions unless we are interested in the total ionic activity for some reason, and at the same time the charges all balance out. If we select the correct “A-” and adjust the relative amounts of “HA” and “NaA”, we end up with a mixture that starts out at a pH that can be predicted via calculation. This is normal when adding proton or hydroxide donors to water, but where buffers are different is the ability to absorb proton or hydroxide inputs without the pH changing much. This is because of the presence of both protonated “HA” and deprotonated “A-” and is useful in situations were the molecules under study cannot tolerate large pH swings, which usually means proteins and other biological molecules. Selecting a buffer requires the concept of the constant of acidic dissociation (Ka) and the negative log of the same (pKa), but between this and Henderson Hasselbalch equation you should have plenty of keywords to play with. I am also supposed to be covering titrations here, but since these are as obsolete as Brønsted-Lowry and really shitty to have to carry out in the lab I’m not going to bother.
submitted by FightingForSarah to SpaceXFactCheck [link] [comments]

General chemistry wrap-up and moving to organic

[https://pubchem.ncbi.nlm.nih.gov/periodic-table/png/Periodic_Table_of_Elements_w_Chemical_Group_Block_PubChem.png ] or [https://ptable.com/#Properties ]
In the last 14 posts, I have attempted to present the main points/useful information from a whole academic year of general chemistry. A significant fraction of the material taught in general chemistry is obsolete, but I am also skipping over any of the information that is actually beneficial to have somewhat memorized, all of the math, etc. Generally speaking, people don’t seem to have much trouble retaining information that is useful to them, so unless you’re having to pass a series of exams I would not worry about any of the details if you don’t want to. Maintaining a degree of rigor and intellectual honesty is important, but at the same time knowing a theory should enhance your understanding of the real world instead of detracting from it.
In any case, we have atomic nuclei with positively charged protons and non-charged neutrons surrounded by somewhat amorphous clouds of negatively charged electron density generated by a discrete number of negatively charged electrons moving around at high speed. How nuclei, orbitals, and electrons interact is chemistry, and given the complexity in chemical reactions that is evident (particularly in biology) it should come as no surprise that the behavior of electrons, elements, and molecules is also extremely complex. We as a species have spent many centuries of unified time and uncountable person-millennia of effort grappling with aspects of the complexity of chemical behavior, before discovering relatively recently that everything is derived from quantum mechanics and none of the simple mathematical models are particularly valid. The discovery of quantum mechanics started in the early 1900s to the 1920s or so in the physics community and has led to a progressive series of major improvements in the way we think about the world that is still underway. The information gained has led to our disastrous exploration of nuclear fission in heavy elements but also to the development of much more potent instrumentation, semiconductors, computers, and a better, if not necessarily more comforting, understanding of the universe that we live in.
Looking at chemistry specifically, our goal as a species needs to be to do as little chemistry as possible while still ensuring our survival. Where chemical reactions are unavoidable, we need to take care to ensure that the resulting waste is as non-toxic, biodegradable, and/or easily denaturable as possible. Simple molecules such as carbon dioxide can cause problems when emitted in bulk, and more complex molecules tend to be nastier in much lower quantities and concentrations (eg polychlorinated biphenyls/PCBs). As creatures with cellular machinery that is mostly made of organic molecules, we are going to be most interested in organic reactions despite our historical inability to make much sense of the complicated electronics and molecular orbitals of organic reactions. Unfortunately, this means that we will not be able to skip as many of the details, and if I want to try for complete coverage I would expect to see a few tens of posts. The main difference between general and organic chemistry is that a significant fraction (possibly even most) of the general chemistry material is obsolete and/or irrelevant, while the majority of organic chemistry material is both important and relevant. So this may take a while, and I’m going to wish that I still had access to the ChemDoodle software that is set up for organic structures. On ubuntu linux, the GChemPaint program seems similar and is free, and I guess that I’m about to find out how well that it works.
I will do my best to relate concepts back to the mental picture of how chemical compounds interact that you are hopefully building up as I introduce them, but as always things are usually going to be messy. The list of high level topics in organic chemistry as defined by my undergraduate study guide is as follows: structure, bonding, intermolecular forces of organic molecules, acids and bases in organic reactions, nomenclature, isomers, principles of kinetics and energy in organic reactions, preparation and reactions of (alkenes, alkynes, aldehydes, ketones, alcohols, sulfides, carboxylic acids, amines, aromatic compounds), organic reaction mechanisms, principles of conjugation and aromaticity, and spectroscopy. I have not yet decided if this is the order in which I would like to present these concepts, but hopefully you can see that this is a large amount of material. As a final note, organic chemistry is mostly the chemistry of hydrogen, carbon, nitrogen, and oxygen with trace quantities of several other elements participating at times. Organic molecules are interesting both because of the wide range of properties and behaviors that they exhibit and also because of our desire to understand our biology, and we are studying mainly the chemistry of the 1s, 2s, and 2p valence orbitals in small atoms.
submitted by FightingForSarah to SpaceXFactCheck [link] [comments]

Chemical bonding and molecular structure

[https://pubchem.ncbi.nlm.nih.gov/periodic-table/png/Periodic_Table_of_Elements_w_Chemical_Group_Block_PubChem.png ]
As with literally everything else, the most appropriate way to think about chemical bonding depends heavily on the context. Generally speaking, chemical bonds are when atoms stick together and require a significant energy input to be broken back apart. Lower energy states tend to be more stable, while higher energy states tend to be less stable. Energy is delivered to molecules mostly as heat, which means molecules colliding with each other and exchanging velocity and hence kinetic energy. Photon absorption is another possibility, but the mechanics behind it are more complicated and can only get in the way at the moment. So, chemical bonds can exist at temperatures between 0 kelvin (absolute zero, no atomic movement at all) and the conditions under which all electrons completely dissociate from the nuclei to form plasma. The strength of the bonds in question and the conditions in which they are located will determine the specifics, but obviously some chemical bonds are much more resistant to high temperature than others. Towards one end, you have compounds like hydrogen peroxide that are fully capable of spontaneously dissociating at room temperature and pressure. In about the middle you have substances like wood that will break bonds and combust under ambient conditions if supplied with an ignition source, and towards the other end you have things like concrete or rock that don’t usually burn very well. However and while combustion is a convenient, easily accessible reaction, I should note that many other reactions also exist, most of which are more complicated than applying heat in an oxygen atmosphere.
Before we get there, I should repeat that chemical bonds “glue” positively charged nuclei together with negatively charged electron density. To have a chemical bond, the valence electrons and orbitals of the bonding atoms need to combine. At one extreme, an electron can be completely transferred from one atom to another, resulting in an ionic compound. The most popular example of an ionic compound is table salt, sodium chloride/NaCl/Na+ Cl-. As can be seen, the highly electronegative chlorine atom is able to completely remove one of the valence electrons on the sodium atom, which despite the resulting charges puts both atoms into a noble gas electron configuration and is hence energetically favorable. At the other extreme, we have bonding electron density being split completely equally between the two atoms. This only occurs when two of the same atom are bonded together (H2, O2, N2, some carbon-carbon bonds, etc) and makes intuitive sense because you would not expect either of two identical atoms in identical chemical environments to be more electronegative than the other. In between these two extremes is a spectrum of bond polarization, with electron density skewed to some extent or another to the more electronegative of the two atoms. Please note that the electronegativity values I linked in the previous post do not take into account any other bonds that influence electron distribution and hence the chemical environments around the atoms in the bond of interest, so that table should be used cautiously.
From a bond strength perspective, maximizing the electron density between the two bonding atoms also maximizes the strength and minimizes the length of the bonds. To put it another way, increased electron density shields the positive charges on the nuclei from each other, allowing the nuclei to be closer together. Consequently, ionic bonds are very weak in the sense that the cations and anions can be easily pulled apart, and covalent bonds that distribute electron density evenly between two atoms are much more difficult to pull apart. For the next part, I will neglect the behavior of ionic compounds (also acids and bases, which behave similarly) to focus on covalent bonding. I am also going to neglect the polarization of covalent bonds towards more electronegative atoms because the distribution of the electron probability density inside the molecular bonding orbitals does not affect our understanding of how these orbitals form. With covalent bonds, there are two main bond types that are helpful to think about. In reality, what actually happens is that the atoms and their atomic orbitals combine to whichever state is accessible and lowest in energy, but the process of generating a set of molecular orbitals for each individual molecule is very labor intensive and does not add much to our understanding.
So, to start out with let’s examine the main organic elements: carbon, oxygen, nitrogen, and hydrogen. Hydrogen is easy to deal with because it bonds with the 1s orbital only, and the 1s orbital is a sphere. The remaining three elements have both a spherical 2s orbital and three 2p orbitals that can participate in bonding, which makes things more complicated. In terms of shape, each p-orbital can be thought of as existing in a 3D cartesian coordinate system with the nucleus at the origin. Each orbital then has two lobes parallel to the x, y, or z axes, with a nodal plane (no electron density) oriented in the other two axes. As an example, the p_x orbital will have two lobes parallel to the x axis and no electron density on the yz plane. In practice, the result will look much more like a sphere cut in half than the balloon-shaped lobes usually depicted, but that’s not all that important. I should also mention that opposite lobes have opposite polarizations, and that a + polarized p-orbital lobe on one atom does not have bonding overlap with – polarized p-orbital lobes on other atoms but will have bonding overlap with + polarized p-orbital lobes on other atoms. This becomes important later on when we get into conjugated systems and can explain some oddball bonding behavior much later on.
Anyway, I still haven’t introduced sigma and pi bonding, so let’s do that. Sigma bonds have the bonding orbitals located directly between the bonding atoms are as a result yield the strongest bonds. Pi bonds depend on the bonding overlap of p-orbitals above and below and/or to either side of the axis directly between the two atoms where a sigma bond would form. Pi bonds still put electron density in between the two nuclei and are still bonds, but cannot be as strong as a sigma bond. Since hydrogen has no valence p-orbitals, it cannot participate in pi bonding schemes, but carbon, nitrogen, and oxygen are all fully capable of donating one or two p-orbitals to pi bonds. If three or more atoms in a row all have p-orbitals in the same plane, the potential exists for all of those p-orbitals to combine into one conjugated pi system, which usually offers energy advantages compared to isolated pi bonds. There is quite a bit more complexity along these lines, but this is mostly dealt with in organic chemistry.
Moving back to sigma bonds, I should first note that the number of bonds that an atom can form in most circumstances is equal to the number of unoccupied electron spaces in its valence shell. So, hydrogen can only form one bond before filling the 1s orbital, boron in theory should form five bonds but in practice is only capable of three with a completely empty p-orbital before running out of bonding volume around the small atom, carbon can form four bonds, nitrogen can form three bonds, oxygen can form two bonds, and fluorine can form one bond. During bonding, an atom will usually be thought of as “owning” a number of electrons equal to the number of its valence electrons (hydrogen one, boron three, carbon four, nitrogen five, oxygen six, fluorine seven). Due to orbital overlap, the electrons in the bonds that are in theory “owned” by the other atoms are also thought of as filling out the valence shell of the bonded atom, and in this manner the atoms in organic compounds can achieve electron configurations close to or equaling noble gas configurations despite all of the atoms in the molecule having fewer than the eight valence electrons required to actually be a noble gas or halogen anion. To put it another way, in the absence of bonding all of the atoms in organic chemistry are severely electron-deficient from a valence shell point of view, with bonding the valence shells can (mostly) all be filled without stacking a bunch of extra electrons (that don’t exist in the big picture – the number of protons and electrons is about equal) onto all of the atoms. This would also generate screamingly unstable accumulations of negative charge, so from an energy perspective bonding works out very well for most or all of the atoms involved.
At this point, I have not said anything about how bonds are actually arranged in space around an atom with both s and p valence orbitals. In the 2 shell where most of organic chemistry happens, the 2s and 2p orbitals all occupy roughly the same volume, which brings us to orbital hybridization and lone pairs. With four valence orbitals, we expect to have four bonding/molecular orbitals, each located in a distinct volume. Having a spherical 2s orbital and three p-orbitals at right angles arranged around the same nucleus is not compatible with this, and is not how atoms participate in bonding. Instead, three bonding arrangements are possible: tetrahedral (sp^3), trigonal planar (sp^2), and linear (sp). In the sp^3 case, the 2s and all of the 2p orbitals combine to form four new orbitals, each with one part s-orbital character and three parts p-orbital character. The hybridized orbitals form bonds as far apart as physically possible, resulting in a uniform bond angle of 109.5 degrees and the tetrahedral configuration. Methane (CH4) is an example of a tetrahedral compound – the sp^3 orbitals on the carbon atom bond with the 1s orbitals on the hydrogens, resulting in a perfectly symmetrical arrangement of bonds around the carbon atom. Ammonia (NH3) is also an example of a tetrahedral compound, although you might not expect that on first inspection. More properly, I should write ammonia as :NH3, which is because a nitrogen atom “owns” five valence electrons and can form three bonds. In this case, the open electron spaces are filled by the three bonding hydrogen atoms, with three nitrogen electrons participating in these bonds. The remaining two valence electrons from the nitrogen occupy the nitrogen sp^3 not already bonding with a hydrogen atom, with the absence of another positively charged nucleus meaning that the lone pair will tend to repel the electron density in the N-H bonds, pushing the hydrogens closer together on one end of the molecule and distorting the ideal 109.5 degree bond angles.
In a trigonal planar sp^2 bond scheme, one of the p-orbitals does not participate in hybridization and is free to participate in pi bonds with other atoms. The loss of one p-orbital means that there are only three hybrid orbitals, each with one part s character and two parts p character. The higher fraction of s character means that sp^2 orbitals will be lower in energy than sp^3 orbitals, although whether or not the sp^2 bond scheme is energetically favorable overall also depends on the chemical environment of the remaining non-hybridized p-orbital. Geometrically, the remaining p-orbital will tend to occupy all of the space apart from the nodal plane, pushing the other three bonds into the nodal plane at about 120 degree angles from each other. A linear sp bond scheme is quite similar to the sp^2 bond scheme, but with two p-orbitals not participating in hybridization. The s-orbital and remaining p-orbital generate two hybrid orbitals with one part s character and one part p character, so sp orbitals are the lowest in energy of any of the hybrid orbitals. With two p-orbitals at right angles taking up much of the available volume, the other bonds will default to the volume along the intersection of the nodal planes of both of the p-orbitals. Since the intersection of two planes is a line, linear bonds will tend to be 180 degrees apart.
Once we start getting into larger third row elements or the d and f blocks, things become much more chaotic and complicated. With the organic bonding mostly described here sufficient to form the basis of all biological processes, you can probably imagine the idiosyncrasies exhibited by the heavier atoms, particularly if you view the d and f orbitals as depicted here (https://i.stack.imgur.com/K5EcA.jpg ). If you are wondering why heavy metal poisoning can be so damaging to human bodies, this is much of the reason why.
submitted by FightingForSarah to SpaceXFactCheck [link] [comments]

Need help ranking basicity for OChem problem

Need help ranking basicity for OChem problem
It's my first week in OChem and I'm stuck on a homework problem. The problem asks to rank the basicity of 4 different compounds given in the form of bond-line structures. We are given 3 attempts to solve the problem correctly, of which I have used 2. On my first attempt, I took the completely wrong approach (used acid rules). On my second attempt, I figured out the chemical formulas and then researched the pKas of their conjugate acids to figure out which is the strongest. This still didn't seem to be right, although I think my approach is on the right track.
The pKas for the conjugate acids for these specific structures are not provided in the textbook. I've never heard analogous structures in this context and could not find a chemistry definition online, so I'm not quite sure what that means. The order displayed in the screen shot below is my most recent attempt. I would appreciate any help.
https://preview.redd.it/ak8zd5b7brc61.png?width=1372&format=png&auto=webp&s=70ee3353540a2e304c64ca1cccf0c9cbae89eefd
submitted by abcara to chemhelp [link] [comments]

[Discussion] Hepatic Metabolism of Oral AAS, Hepatotoxicity, and Liver Support

I know this is a long write up, the first half is biochemistry and what happens on a cellular level. The second half is more pertaining to the average AAS user, including a deeper dive into liver functioning tests and liver support. I highly recommend at least reading the second half, especially the Liver Support section.
Hepatotoxicity is a word that is frequently thrown around, everyone’s heard it, everyone thinks they know what it is, but once you ask something beyond surface level, you get a whole lot of conflicting answers. Let’s dive into it.
Overview/Background/General Information/What the fuck actually happens?
Drug Metabolism: The human body identifies almost all drugs as foreign substances and subjects them to various chemical processes to make them suitable for elimination. Drug metabolism is typically split into two phases: Phase 1 (oxidation via Cytochrome P450, reduction, and hydrolysis) tends to increase water solubility of the drug and can generate metabolites. Phase 2 further increases water solubility of the drug, inactivating metabolites, thus preparing it for excretion.
17α-Alkylated Anabolic Steroids. These AAS contain a methyl or ethyl group on the C17α position, allowing for oral activation. This modification allows the drug to survive hepatic metabolism, limiting the amount of steroid that is broken down, allowing for more drug to reach the bloodstream. Without this modification, the drug is completely broken down by the liver, never reaching systemic circulation. This initial process is called First Pass Metabolism.
First pass metabolism: After a drug is swallowed, it is absorbed by the digestive system and enters the hepatic portal system. It is carried through the portal vein into the liver before it reaches the rest of the body. The liver metabolizes many drugs, sometimes to such an extent that only a small amount of active drug emerges from the liver to the rest of the circulatory system. This first pass through the liver may greatly reduce the bioavailability of the drug. Some oral steroids have a very low bioavailability due to first pass metabolism, thus injectable versions may be used to prevent the initial breakdown, effectively increase bioavailability and reducing liver stress.
In short: Oral Steroid (active) -> Hepatic Breakdown -> Metabolite (inactive)
In the case of oral AAS, hepatic metabolism can convert an active drug into its inactive form; C17α methylation prevents this. Why is this modification known to be hepatotoxic? The primary enzyme that normally breaks down hormonal steroids (such as endogenous DHEA, testosterone, estradiol, etc) is 17β-Hydroxysteroid dehydrogenase, 17β-HSD, (and to a minor extent the Cyp450 family) which can no longer break down the methylated drug, thus the liver finds an alternative route for metabolism. The actual specific process is still relatively unknown, but involves a variety of oxidation reactions, inducing an increase of free oxygen radicals within the hepatocytes (liver cells), causing cell death due to oxidative stress.
There is another hypothesis which involves the presence of androgen receptors within the liver. The C17α methylated oral steroid, that is no longer properly broken down, will bind to these receptors, causing a drastic increase of androgenic activity within the liver, leading to hepatoxicity.
In my opinion, it is a mixture of both. Many studies show a direct correlation between the androgenic effect of the oral steroid and the amount of hepatoxicity. The exact link between the two is yet to be determined.
In general, the greater the affinity of C17α methylated oral steroid for the androgen receptor, the more hepatoxicity occurs.
Hepatotoxicity is an overlying term: the specifics related to AAS use are Cholestasis (blockage of biliary flow), Steatosis (accumulation of fatty lipids within the liver), Zonal Necrosis (hepatocyte death within a specific zone of the liver), and Peliosis Hepatitis (vascular lesions leading to liver enlargement).
Cholestasis is a condition where bile cannot flow from the liver to the duodenum. It is the most common condition resulting from oral AAS use. In short, bile is continuously produced but cannot leave the liver, causing build up, backflow, and eventually hepatocyte death. Differential symptoms of cholestasis include but are not limited to pruritus (itchiness), jaundice (yellowing of the skin and whites of the eyes), pale stool, and dark urine.

Liver Functioning Tests: What do they mean and why are they relevant?
AST: Aspartate Transaminase: This alone is not a good indication of liver damage. AST is found in abundance within both cardiac and skeletal muscle. An elevated AST value can be caused by something as minor as weightlifting.
ALT: Alanine Transaminase: ALT is found specifically within the liver and is released into the plasma when significant liver stress, including hepatocyte death, occurs. An elevated value is of concern.
ALP: Alkaline Phosphatase: ALP is found within the hepatobiliary ducts. An elevated value is commonly indicative of obstruction and bile buildup, signifying cholestasis.
GGT: Gamma-glutamyl Transferase: GGT is an enzyme that is found in many organs throughout the body, with the highest concentrations found in the liver. GGT is elevated in the blood in most diseases that cause damage to the liver or bile ducts.
5’-nucleotidase: The concentration of 5’-nucleotidase protein in the blood is often used as a liver function test in individuals that show signs of liver problems. ALP can be elevated due to both skeletal disorders and hepatic disorders. 5’-nucleosidase is elevated ONLY with hepatic stress, not skeletal, thus allowing for differentiation.
Putting it all together: Cholestasis can be suspected when there is an elevation of both 5'-nucleotidase and ALP enzymes. Normally GGT and ALP are anchored to membranes of hepatocytes and are released in small amounts in hepatocellular damage. In cholestasis, synthesis of these enzymes is induced, and they are made soluble. GGT is elevated because it leaks out from the bile duct cells due to pressure from inside bile ducts. As hepatocyte damage continues, ALT, AST, and unconjugated bilirubin will begin to rise.
In short: Initial liver stress causes 5’-nucleiotidase and ALP to rise, shortly after GGT rises, then finally AST and ALT rise. Thus, with only AST and ALT values, it is difficult to determine the cause and extent of hepatic damage.

Liver Support: NAC/TUDCA/Liv52
NAC: N-Acetyl Cystein
NAC is a prodrug of L-cysteine, a precursor of the biological antioxidant glutathione which is able to reduce free radicals within the body. Free radicals, which as discussed above, are associated with causing extensive hepatocyte damage due to the oxidative breakdown of C17α methylated AAS.
In addition to its antioxidant action, NAC acts as a vasodilator by facilitating the production and action of nitric oxide. This property is an important mechanism of action in the prophylaxis of contrast-induced nephropathy and the potentiation of nitrate-induced vasodilation.
Multiple studies have constantly showed NAC decreasing liver functioning tests and improving liver function and mitigating cholestasis. NAC had the ability to vastly improve markers of kidney function and was actually able to even double the rate of sodium excretion, indicating that NAC is may be useful in preventing water retention.
In short, NAC has a vast number of benefits, including hepatoprotective (liver), nephroprotective (kidney), and neuroprotective (neural), and anti-inflammatory effects that have been constantly demonstrated thru literature. Moreover, NAC can and should be used for year-round support since the adverse effects are incredibly mild. There is absolutely NO reason to not be taking NAC.

TUDCA: Tauroursodeoxycholic acid
TUDCA is a bile acid taurine conjugate form of UDCA. As discussed above, during cholestasis, bile builds up, creating backflow and inducing hepatocyte death thru apoptosis. Apoptosis, or programmed cell death, is largely influenced by the mitochondria. If the mitochondria are distressed, they release the molecule cytochrome C. Cytochrome C initiates enzymes called caspases to propagate a cascade of cellular mechanisms to cause apoptosis. TUDCA prevents apoptosis with its role in the BAX pathway. BAX, a molecule that is translocated to the mitochondria to release cytochrome C, initiates the cellular pathway of apoptosis. TUDCA prevents BAX from being transported to the mitochondria, effectively inhibiting hepatocyte death.
Furthermore, TUDCA aids in the processing of toxic bile acids into less toxic forms, resulting in decreased liver stress, further preventing hepatocyte death. Moreover, TUDCA aids in the transport of bile from the liver into the duodenum, effectively unblocking the build up causing cholestasis. Finally, TUDCA has been proven to be an effective treatment for the necro-inflammatory effects of Hepatitis. Study after study has shown that TUDCA greatly improves liver enzyme values.
Why do we recommend only using TUDCA with hepatotoxic oral steroids? The idea is that TUDCA induces liver damage when there is no hepatotoxicity present… but after reading the above, does that make sense? It does not. I could not find any literature showing that TUDCA induces liver toxicity. The recommendation instead is due to the negative effects of TUDCA on cholesterol values. TUDCA has been shown to greatly decrease HDL levels when taken for extended periods of time. The idea is, if you have a healthy functioning liver, there is no reason to take TUDCA for long periods of time since all you’re doing is decreasing HDL values. That being said, after doing the research and seeing the vast benefits of TUDCA (included bellow, not a comprehensive list), I am beginning to change my perspective on TUDCA use with only hepatotoxic oral AAS.
In short, TUDCA prevents hepatocyte death, enhances hepatocyte function, exhibits anti-inflammatory effects on the liver, neutralizes toxic bile, and prevents bile build up that was caused by the alternative metabolism of C17α methylated AAS.
***THERE IS NO EVIDENCE THAT I HAVE COME ACROSS THAT SHOWS THAT TUDCA ITSELF INDUCES LIVER DAMAGE WHEN USED WITHOUT HEPATOTOXIC DRUGS**\*
TUDCA has a variety of other benefits outside the liver, but I will not go into them this time. In short:
Sources

Liv52
Liv52 is an herbal liver support. There have been medical studies conducted on Liv.52 in recent years, many of which involve its ability to protect the liver from damage by alcohol or other toxins. Liv52 has been shown to exhibit antiperoxidative function, antioxidant effects, anti-inflammatory, diuretic effects and neutralization of toxic products within the liver.
“The results demonstrated that the patients treated with Liv-52 for 6 months had significantly better child-pugh score, decreased ascites, decreased serum ALT and AST. We conclude that Liv-52 possess hepatoprotective effect in cirrhotic patients. This protective effect of Liv-52 can be attributed to the diuretic, anti-inflammatory, anti-oxidative, and immunomodulating properties of the component herbs.”
“Liv.52 enhanced the rate of absorption of ethanol and rapidly reduced acetaldehyde levels, which may explain its hepatoprotective effect on ethanol-induced liver damage.”
“Liv.52 administration reduced the deleterious effects of ethanol. The concentration of acetaldehyde in the amniotic fluid of ethanol-consuming animals was 0.727 microgram/ml. Liv.52 administration lowered it to 0.244 microgram/ml. The protective effect of Liv.52 could be due to the rapid elimination of acetaldehyde.”
That being said, there is conflicting research on Liv52. The studies either show hepatoprotective function or no effect, positive or negative.
“There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.”
In short, Liv52 can be used if you have the additional funds, it is not the end-all-be-all but can be used as an adjunct. It is an incredibly cheap drug that may improve liver function and exhibit hepatoprotective effects. IT SHOULD IN NO WAY YOUR ONLY LIVER SUPPORT MEDICATION, but there is nothing wrong with using it.
submitted by Essindeess to steroids [link] [comments]

F | 31 | 453.59 kg | 82.1 kg | 409.3 Wilks | 2020 RPS Fall Throwdown at Rivercity Barbell, Dayton, KY

tl;dr summary: almost bombed, totaled 1000, Pretzel puts on a show of ovarian fortitude.
This is going to be long, in part because I like to go back and read these to reflect on what I learned every meet, and because when I was a noob I needed more experienced lifters to tell me literally everything that could possibly happen on meet day so I could mentally prepare myself. I'm also going to be pretty transparent about the things I had going on in my non-lifting life leading into this meet, because October is ADHD Awareness Month, and because the longer I've been in the sport, the more I understand how real life shows up on the platform. It's important to remain cognizant of what you're overcoming, on and off the platform. Skip about halfway down for the actual lifting. Videos of all 9 attempts are split between IG and imgur links, included below.
BACKGROUND
This was meet number six for me, my third in wraps and my second in the 181 class. Since my last meet in November 2019, I have been working with Lones Green (calloused hands), training conjugate. He has been great to work with, willing to make adjustments where my body demands it (for instance, dealing with elbow tendinitis) and willing to push me where I need it. He's been calling for this total (a little higher tbh) since I registered for a meet in May 2020, which obviously didn't happen. His style is based in conjugate, with traditional max effort and dynamic effort days, with a lot of training volume. Once I got acclimated to the volume, I loved it. I get a wide range of accessories to address weak points and build up my strong points, and it's generally just a fun way to lift. It's built incredible work capacity which kept me comparatively fresh by the time it was time to deadlift and built the ability to both rep out big weight and smoke new PR singles pretty regularly. I've also stayed healthy, which in this sport is a minor miracle. I plan to continue with this style as long as Lones wants to keep coaching and my body holds up.
Leading into this meet, I had a lot of personal life things going on. Some were very positive, but some were fairly traumatic, and either way, it's a big emotional/mental/spiritual demand while also prepping for a meet. I moved in with my boyfriend at the end of August, which has been great! He has been a champ all the way through, and really is the MVP of this story. But telling my family went really, really poorly, and feeling that kind of rejection from the most important people in my life was one of the most painful things I've ever felt. Things have settled there, but it was really rough for a while. I also don't really recommend moving at six weeks out during the busiest work week of the entire year, but sometimes it be like that.
The other thing was getting assessed, diagnosed, and then trying a medication for ADHD. I'm a 31 (relatively) accomplished attorney, and had no idea until quarantine that the constant feeling of "I'm lazy and why can't I cope like everyone else" wasn't normal. While it's a relief to know what the problem is, and to know that there are options to address my deficits, it's also crushing to find out that I have struggled against my own brain chemistry for 31 years and had no idea, and just spent that time beating myself up instead. There is an intense grieving process that goes with the diagnosis. I don't want to be this way, but here we are, and now it's time to fight, this time with all the correct information. I'm about five weeks into my first shot at medication, and it has not gone super well, but I know I have other options and I'm hopeful those work a little better for me. Shoutout to adhd for being an amazing resource; if you're struggling too, or think this is something you may be coping with, that's the most supportive subreddit I've ever seen. I know that my real name is very easily connected with this account, and I don't care. I'm not ashamed I've been medicated for depression for 6 years, so I am not going to be ashamed of the ADHD either. I'm not the only attorney in the world with ADHD, and I won't hide if it helps someone else get help.
Finally, ten days out from competing, two of the people that I've been closest to since I moved to this area completely iced me out. I don't want to doxx them and I'm not going to get into the dramatic details or try to make them look like the devil, but this sucked. A lot. I didn't want to let it shake me up, but these two are also competitors, and to do this to someone you purportedly care about right before competition is not an accident. I don't wish them ill and I know I'll be better in the long term without that kind of petty toxicity in my life, but wow, not having them cheering for me this time--out of nowhere--shook me up. A lot. It showed up on the platform. I wish I were strong enough to say it didn't, but I'll own my mental weakness here. However, this experience really highlighted all the people who are absolutely in my corner, and that has been a gift.
okay enough of Pretzel's diary, let's lift.
SQUAT (1/3)
lol. Just lol. This was an all systems failure that I have never experienced on the platform and hope to never experience again. Guy wrapping me was outstanding and my bf was great at keeping me calm, but shew lawd 1/10 do not recommend. I didn't miss a single squat in training. I just shit the bed.
1st attempt: 390 all i can say is wtf. This is easy weight for me, and even though I had been training with an up call for weeks, I jumped the call, realized I jumped it, and did this bizarre 1.5 squat. I mean, WTF? It was light, so I jumped to 410 and tried to shake it off.
2nd attempt: 410 Narrator: She did not shake it off. At this point I was DISTRAUGHT. I hadn't ever missed a freaking opener, let alone stared bombing out in the face. These guys were on the way.
3rd attempt: 410, 10 lb PR. Absolutely not the weight I came for, but bf jumped in to back spot and we had a little Titanic moment. He told me when I walked up not to get a call, just squat because I know how to do that. Turns out yes I do. 3 whites, we're in the game. As I've said and will say repeatedly, I think his believing that I could do it popped me back up out of the hole, because I was mentally crushed by this lift.
Lessons: I got way too amped beforehand. Less is more there. I may not use ammonia at all going forward, because it didn't help me here at all, and I didn't use it other than my deadlift opener the rest of the day. I need to approach the bar calm and confident, not WILDIN OUT. I also need to trust that I am actually capable of finding depth on my own, pretty easily, and not get so worked up on missing a rep on depth that I do stupid things like this.
BENCH (2/3)
I was cramping pretty good between attempts but this went okay.
1st: 175, old meet PR for a smokeshow.
2nd: 190, 15 lb platform PR. pretty blown away with how easily this went up. Really happy with this bench.
3rd: 200, just not quite. I'm proud of how I handled it, just wish I didn't get a back cramp when the weight came off my chest. I know it's going to be there next time, and I have some ideas on tweaking my arch and salt intake to mitigate the cramps that haunt me EVERY SINGLE MEET.
DEADLIFT (3/3)
Honestly, I was dead in the water at this point. I felt like the day was a failure, which is silly because I was going to get a PR total on my opener, but it wasn't what I wanted going in, and I couldn't get my head right. Fortunately, I got the greatest back slaps of all time from bf, who by this point should be able to add my lifts to his total, because he was carrying me. I have had a complex for years, honestly, about being a weak puller, and just didn't think I could pull off the 1k total I wanted resting on this lift. Well...
1st: 355, smoke.
2nd: 380, good, 5 lb PR over my last meet and heaviest thing I've ever pulled off the floor til about 7 minutes later.
3rd: 400. Three. White. Lights. 25 lb lifetime PR. I knew I HAD to get this pull to save my day. I failed a 425 pull with reverse bands six weeks out. I thought I had no shot. And then it moved like this. It didn't stick off the floor, I didn't catback, it just went up. I got my 1000, my 400 pull the first time I ever attempted it, and I cried profuse quantities of happy tears afterwards.
TAKEAWAYS
Overall, despite the incredibly crappy start, I went 6/9 and still pulled off a thousand freaking pound total with PRs across the board. That's a 50 lb overall PR. Six meets deep, PRs are not a given, and I am thrilled to still be posting big ones even on not-my-best day. That final pull honestly took all the sting out of my squats, which in training had been by FAR my strongest lift. I missed deadlifts all over the place in training and then holy hell did they show up when it counted. Deadlift, maybe you and I can be friends after all.
According to the RPS, I'm a pro now, which is worth a lululemon athlete discount and not much else. I put up numbers I never thought were possible, and I'm set up for a ridiculous squat PR next go around (because no way am I repeating that nonsense). I wanted to break after those first two misses, and my people and my innate stubbornness wouldn't let me, and I am very thankful.
The end. If you read this whole thing, you've been procrastinating too long. Get back to work.
submitted by pretzel_logic_esq to powerlifting [link] [comments]

🔬 Curowhite and the Color of Curcumin 🔬

We have been getting a lot of confusion and questions on the color of Curowhite on our Facebook page, so I figured I would make a post here to address it. I am sure some people here are curious as well. To start, one of the major questions we have been getting is whether Curowhite is bleached to get rid of the color. I think many people are unaware of just how color works, which is why many people immediately jump to what they have experienced before. Many people have seen how chlorine bleach gets rid of color, so they fall back to that. I'll go through the details to clear things up.
What is color? Well color is simply our eyes interpreting the wavelengths of light being reflected back to us from an object. If an object is white, that means that the entire spectrum of visible light is being reflected back to our eyes. If we were to take out part of that spectrum before it reflected back to our eyes, we would see it as a specific color. In curcumin's case, we take out the blue hues, which means our eyes see the curcumin as orange. If we remove all wavelengths, we see black. It's all just our eyes interpreting the wavelengths of light being reflected back to us by objects.
So why is curcumin orange? Well from a chemistry perspective, color arises from the presence of a chromophores. Chromophores are parts of a molecule that form a conjugated pi system, which are made up of double carbon-carbon bonds. When you have a conjugated pi system in a molecule, they are able to capture photons as they pass. Since they are capturing some photons, they are absorbing some of the wavelengths of visible light, leading to only part of the spectrum being reflected back to our eyes. That's how color is made. Parts of the molecule are able to capture certain photons as they pass. Lengthening a conjugated system with more unsaturated bonds in a molecule will tend to absorb longer wavelengths of light. So the number of double carbon-carbon bonds in the conjugated pi system in a molecule will dictate which wavelengths are absorbed, and consequently which wavelengths are able to reflect back to our eyes. Chromophores are also how most HPLCs and UPLCs "see" the molecules they are assaying. They have UV detectors on them, which are measuring the reflectance off the analytes. The same goes for UV-VIS machines.
So why is Curowhite white? Well Curowhite is made by converting the curcuminoids in tumeric into tetrahydro curcuminoids, hexahydro curcuminoids and octahydro curcuminoids through a process called hydrogenation. This breaks the double carbon-carbon bonds on the central hydrocarbon chain in the curcuminoids. This breaks the conjugated pi system, which no longer allows photons to be captured as they pass. This means that the hydrogenated curcuminoids in Curowhite will reflect back the entire spectrum of visible light, not absorb the blue hues like normal curcuminoids would.
Here is an image I made to illustrate.
So you can see that the process of hydrogenating the curcuminoids removes the conjugated pi system, which removes the color! So how does chlorine bleach remove color? Well it does that through oxidation. It attacks the chromophores in a molecule by oxidizing them. It's a different process, but he concept is the same. You are removing the double carbon-carbon bonds in a conjugated pi system, which stops the molecules ability to capture photons as they pass. Bleaching is not used in the production of Curowhite, and the hydrogenation process of the curcuminoids actually improves their bioavailability and effects compared to normal curcuminoids. It's actually a really ingenious process. Curowhite also then encases the hydrogenated curcuminoids in a cyclodextrin, which improves bioavailability even more, and makes it water soluble. So that is how they make a curcuminoid product that is white and water-soluble!
submitted by MisterYouAreSoDumb to NootropicsDepot [link] [comments]

LAC Highlights #20: Carleton College

Hi everyone! I hope you all are doing well!
This is the 20th entry in LAC highlights. You can see other LAC or public university highlights written here:
Pomona is an amazing college by u/barronsoverpr
Williams is an amazing school by u/Rob-Barker
LAC Highlights #1: Harvey Mudd College
LAC Highlights #2: Middlebury College by u/ashelover
LAC Highlights #3: Swarthmore College
LAC Highlights #4: Amherst College
LAC Highlights #5: Wellesley College
LAC Highlights #6: St. John's College in Annapolis, Maryland and Santa Fe, New Mexico
LAC Highlights #7: Macalester College by u/slider501
LAC Highlights #8: Reed College
LAC Highlights #9: Grinnell College
LAC Highlights #10: Lewis and Clark College by u/eat_your_spinch
LAC Highlights #11: Smith College
LAC Highlights #12: Vassar College
LAC Highlights #13: A special highlight on all the Oregon liberal art colleges! by u/eat_your_spinch
LAC Highlights #14: Barnard College
LAC Highlights #15: Bryn Mawr College
LAC Highlights #16: Wesleyan University
LAC Highlights #17: Hamilton College
LAC Highlights #18: Bowdoin College
LAC Highlights #19: Colorado College
Public University Highlights #1: Iowa State University
Public University Highlights #2: Virginia Tech
Public University Highlights #3: Utah State University
Public University Highlights #4: George Mason University
Public University Highlights #5: Cal Poly SLO
Public University Highlights #6: Temple University
Public University Highlights #7: The University of Mary Washington
Public University Highlights #8: The University of Iowa
Public University Highlights #9: SUNY Stony Brook: co-written with u/dearwikipedia
Public University Highlights #10: The College of William and Mary
Public University Highlights #11: The Colorado School of Mines
Public University Highlights #12: UMD College Park by u/pinklemonade11
Public University Highlights #13: The University of Washington
Public University Highlights #14: The Ohio State University written by u/Bucknut2014
A special Carnegie Mellon University highlight by u/dinofa
A few of the most underrated colleges (from what I've seen) by u/allthelovely-people
An Introduction to the Little Ivies by u/allthelovely-people
Colleges that Change Lives: More Underrated Colleges by u/allthelovely-people

This highlight will be talking about Carleton College, a LAC located in Northfield, Minnesota. Here are some great things about Carleton:
I hope this helped!
Best of luck! I truly hope all the seniors on A2C get into their top choices this winter and spring!

Have a nice day!
submitted by eccentricgalaxy to ApplyingToCollege [link] [comments]

Need Advice - Emailing Graduate School Advisor

I am sending out my first email to a potential graduate school advisor and I am a little nervous. I am really interested in this professor's work and the school has an amazing environmental engineering program that I am considering. I was hoping someone could take a look at what I've wrote and give me some advice. I am not really sure what to include or how to format these sorts of emails
I have seen it suggested that I read a recent paper of the advisor to reference in the email. I found one that particularly interested me and I percieve to be representative of what their lab studies. The only concern I have is that the advisor is the last author of six. I don't really know the best way to refer to the paper in the email. Would it be wrong to say "you wrote" or should I say "the paper said"? Also, should I even be choosing this paper to reference if they are the last author? (I'm not saying being the last author is bad but I do assume it means they contributed less than the others). I was going to choose a recent paper they published as #1 author, but it has more to do with environmental engineering ethics than the research in thier lab.
I will also be including my resume attached to the email!
Email text:
Dear Dr. ____,
My name is ________ and I am in my last year at the University of X studying Environmental Science with a minor in chemistry. I am interested in obtaining a graduate degree at Y University - particularly a Master's of Science in Environmental Engineering.
I find the research being conducted in your lab to be very interesting! What you mention on your lab website about bioaugmentation of indigenous microbes and the use of horizontal gene and plasmid conjugal transfer sounds fascinating. I recently read a paper you co-authored, "Investigating the mycobiome of ..." I really enjoyed reading it and I learned more about PAHs, something I don't have too much experience with. It's interesting that the five most abundant PAHs identified in the samples differed from the top 5 PAHs in creosote listed by the American Wood Protection Association. It was suggested that this may be due to weathering. Would this be physical weathering or could it be from microbial degradation? I am interested to know if there would be a way to identify which kind of degradation occurred more. Perhaps there is a by-product of microbial degradation that would be present in the soil as well? I also found it particularly interesting that the data differed from others showing that fungal strains were not inhibited by increasing PAH concentrations. You noted that there was evidence that ascomycetes may outcompete basidiomycetes contrary to previous studies. In my work at the X Center, we explored the use of basidiomycetes as barrier material for coal ash ponds. Although we focused on different contaminants, it is still interesting to contemplate this finding in my own work.
I was hoping you might tell me if you are accepting graduate students for Fall of 2021? I believe your lab would be a great fit for me. As I mentioned previously, I have research experience in bioremediation with the X Center as well as microbial ecology experience in the Y lab at the University of X that I believe could be a good addition to your cohort. I have attached my resume to this email where I discuss these experiences in more detail.
If you have any advice about graduate school or bioremediation studies, I would also love to hear them! I look forward to hearing from you soon!

Edit: I am grossly aware of how many times I used the word 'interesting' so I will definitely fix that for the actual email.
submitted by libermeister to Environmental_Careers [link] [comments]

Lupine Publishers | The Creation of C13H20BeLi2SeSi. The Proposal of a Bio- Inorganic Molecule, Using Ab Initio Methods for The Genesis of a Nano Membrane

Lupine Publishers | The Creation of C13H20BeLi2SeSi. The Proposal of a Bio- Inorganic Molecule, Using Ab Initio Methods for The Genesis of a Nano Membrane
Lupine Publishers | An archive of organic and inorganic chemical sciences


Abstract
The work is an evolution of research already begin and in development. Therefore, we can observe a part that has already been commented that presents the whole development of the research from its beginning. Preliminary bibliographic studies did not reveal any works with characteristics studied here. With this arrangement of atoms and employees with such goals. Going beyond with imagination using quantum chemistry in calculations to obtain probable one new bio-inorganic molecule, to the Genesis of a bioinorganic membrane with a combination of the elements Be, Li, Se, Si, C and H. After calculation a bio-inorganic seed molecule from the previous combination, it led to the search for a molecule that could carry the structure of a membrane. From simple molecular dynamics, through classical calculations, the structure of the molecule was stabilized. An advanced study of quantum chemistry using ab initio, HF (Hartree-Fock) method in various basis is applied and the expectation of the stabilization of the Genesis of this bio-inorganic was promising. The calculations made so far admit a seed molecule at this stage of the quantum calculations of the arrangement of the elements we have chosen, obtaining a highly reactive molecule with the shape polar-apolar-polar. Calculations obtained in the ab initio RHF method, on the set of bases used, indicate that the simulated molecule, C13H20BeLi2SeSi, is acceptable by quantum chemistry. Its structure has polarity at its ends, having the characteristic polar-apolar-polar. Even using a simple base set the polar-apolar-polar characteristic is predominant. The set of bases used that have the best compatible, more precise results are CC-pVTZ and 6-311G (3df, 3pd). In the CC-pVTZ base set, the charge density in relation to 6-311G (3df, 3pd) is 50% lower. The structure of the bio-inorganic seed molecule for a bio-membrane genesis that challenge the current concepts of a protective mantle structure of a cell such as bio-membrane to date is promising, challenging. Leaving to the biochemists their experimental synthesis.
Introduction
The work is an evolution of research already begin and in development. Therefore, we can observe a part that has already been commented that presents the whole development of the research from its beginning. A small review of the main compounds employed some of their known physicochemical and biological properties and the ab initio methods used. Preliminary bibliographic studies did not reveal any works with characteristics studied here. With this arrangement of atoms and employees with such goals. So, the absence of a referential of the theme. The initial idea was to construct a molecule that was stable, using the chemical elements Lithium, Beryllium, alkaline and alkaline earth metals, respectively, as electropositive and electronegative elements - Selenium and Silicon, semimetal and nonmetal, respectively. This molecule would be the basis of the structure of a crystal, whose structure was constructed only with the selected elements. The elements Li, Be, Se and Si were chosen due to their physicochemical properties, and their use in several areas of technology [1-4]. To construct such a molecule, which was called a seed molecule, quantum chemistry was used by ab initio methods [5,6,7]. The equipment used was a cluster of the Biophysics laboratory built specifically for this task. It was simulated computationally via molecular dynamics, initially using Molecular Mechanics [8-24] and ab initio methods [5,6,7]. The results were satisfactory. We found a probable seed molecule of the BeLi2SeSi structure predicted by quantum chemistry [23]. Due to its geometry, it presents a probable formation of a crystal with the tetrahedral and hexahedral crystal structure [23].
The idea of a new molecule for a crystal has been upgraded. Why not build a molecule, in the form of a lyotropic liquid crystal [25] that could be the basis of a new bio-membrane? For this, the molecule should be amphiphilic, with polar head and apolar tail. Are basic requirement of the construction of a bio-membrane [25]. Then it is necessary to add a hydrophobic tail, with atoms of carbon and hydrogen. Therefore, the molecule seed with a polar hydrophilic “head”. So, would a new amphiphilic molecule. Several simulations were performed, always having as initial dynamics the use of Molecular Mechanics [8-24] for the initial molecular structure, moving to ab initio calculations of quantum chemistry. All attempts were thwarted. Quantum calculations of quantum chemistry did not accept the seed molecule as the polar head, even changing its binding structure. The silicon atom binds in double bond with the carbon chain and Selenium. It binds in double with beryllium and is simple with the two lithium atoms, thus making a stable molecular structure for Molecular Mechanics [8-24], Mm+ and Bio+ Charmm [26]. But in quantum calculations the seed molecule changed all its fundamental structure [1]. The linear structure of the tail with the polar head, in the form of a rope climbing hook, collapsed, bending toward a polar tail. In another simulation carried out the Selenium was connected in double bond to two atoms of Carbon added in double bond. As the +6 polarities of the selenium neutralized with the atoms two atoms of lithium, forming a wing. In the double bonded sequence is the Carbon with the Silicon, and this in double bond with the Beryllium. A new structure for a probable lyotropic liquid crystal has now been formed. A polar tail with the seed molecule undone but retaining the five base atoms of its fundamental structure [25]. The structure after Molecular Mechanics, Mm+ and Bio+ Charmm [26], the shape of the molecule obtained had a structure like a boomerang. After calculations ab initio, the polar tail was undone. The Beryllium atom did not remain in the structure of the molecule, releasing itself from it. There is then a new idea. Why not separate the electropositive and electronegative elements in two polar heads? This would completely change the concepts known so far of a biomembrane with a lipid bilayer. The next challenging step of building a bio-membrane that runs away from known concepts, with a single layer, with two polar heads and its non-polar backbone. Would it be a new way to have a bio-membrane? A challenge for quantum chemistry.
Then he concentrated the calculations on the probable structure of the molecule with polar ends. Separately then in pairs the atoms of Selenium with Beryllium and Silicon with the two bonds. Again, the attempt failed, in quantum calculations. Beryllium was disconnected from the basic structure of the new molecule, polarpolar- polar polar structure. They have decided to further innovate the theory and “challenge” quantum chemistry. Add an aromatic ring to the polar head. The polar-polar-polar linear structure was now maintained, with a six-carbon cyclic chain. At a polar end, the Silicon is bonded to three atoms of the Hydrogen and is connected to a Carbon from the central chain. This one connected to the two atoms of the Lithium and a polar central carbon chain. At the other polar end, the six-carbon cyclic chain attached in single bond to the carbonic chain. The cyclic chain with simple bonds, having at its center the Selenium with six bonds to the cyclic chain and a double with the Beryllium, thus forcing two more covalent bonds. Now with a +2 cationic head, the dynamics of the minimization energy with Mm+ and Bio+ Charmm [26] calculations have maintained a stable structure of the molecule. A polar head like a “parabolic antenna”, with folded edges outward with the Hydrogen atoms. The expected, the obvious, Beryllium playing the role of the “LNB (Low Noise Block) receiver”. We then proceeded to the ab initio calculations in several methods and basis, testing various possibilities with ab initio methods. The polar-apolar-polar (parabolic) molecule in ab initio calculation, by RHF [5-6,27-32] in the TZV [33,34] sets basis was shown to be stable by changing its covalent cyclic chain linkages, which was expected, (Figure 2). The set of bases used was that of Ahlrichs and coworker’s main utility are: the SV, SVP, TZV, TZVP keywords refer to the initial formations of the split valence and triple zeta basis sets from this group [33,34]. Calculations continue to challenge concepts, experimenting. Going where imagination can lead us, getting results that challenge concepts.
Selenium
Selenium is found impurely in metal sulfide ores, copper where it partially replaces the sulfur. The chief commercial uses for selenium today are in glassmaking and in pigments. Selenium is a semiconductor and is used in photocells. Uses in electronics, once important, have been mostly supplanted by silicon semiconductor devices. Selenium continues to be used in a few types of DC power surge protectors and one type of fluorescent quantum dot [2]. Although it is toxic in large doses, selenium is an essential micronutrient for animals. In plants, it sometimes occurs in toxic amounts as forage, e.g. locoweed. Selenium is a component of the amino acids selenocys teine and selenomethionine. In humans, selenium is a trace element nutrient that functions as cofactor for glutathione peroxidases and certain forms ofthioredoxin reductase [45]. Selenium-containing proteins are produced from inorganic selenium via the intermediacy of selenophosphate (PSeO3 3−). Selenium is an essential micronutrient in mammals but is also recognized as toxic in excess. Selenium exerts its biological functions through selenoproteins, which contain the amino acid selenocysteine. Twenty-five selenoproteins are encoded in the human genome [46]. Selenium also plays a role in the functioning of the thyroid gland. It participates as a cofactor for the three thyroid hormonedeiodinases. These enzymes activate and then deactivate various thyroid hormones and their metabolites [47]. It may inhibit Hashimotos’s disease, an auto-immune disease in which the body’s own thyroid cells are attacked by the immune system. A reduction of 21% on TPO antibodies was reported with the dietary intake of 0.2 mg of selenium [48]. Selenium deficiency can occur in patients with severely compromised intestinal function, those undergoing total parenteral nutrition, and [49] in those of advanced age (over 90).
Silicon
Silicon is the eighth most common element in the universe by mass, but very rarely occurs as the pure free element in nature. It is most widely distributed in dusts, sands, planetoids, and planets as various forms of silicon dioxide (silica) or silicates. Over 90% of the Earth’s crust is composed of silicate minerals, making silicon the second most abundant element in the Earth’s crust (about 28% by mass) after oxygen [11]. Elemental silicon also has a large impact on the modern world economy. Although most free silicon is used in the steel refining, aluminium-casting, and fine chemical industries (often to make fumed silica), the relatively small portion of very highly purified silicon that is used in semiconductor electronics (<10%) is perhaps even more critical. Because of wide use of silicon in integrated circuits, the basis of most computers, a great deal of modern technology depends on it [2]. Although silicon is readily available in the form of silicates, very few organisms use it directly. Diatoms, radiolaria and siliceous sponges use biogenic silica as a structural material for skeletons. In more advanced plants, the silica phytoliths (opal phytoliths) are rigid microscopic bodies occurring in the cell; some plants, for example rice, need silicon for their growth [50,51,52]. There is some evidence that silicon is important to nail, hair, bone and skin health in humans, [53] for example in studies that show that premenopausal women with higher dietary silicon intake have higher bone density, and that silicon supplementation can increase bone volume and density in patients with osteoporosis [54]. Silicon is needed for synthesis of elastin and collagen, of which the aorta contains the greatest quantity in the human body [55] and has been considered an essential element [56].
Methods
The steric energy, bond stretching, bending, stretch-bend, out of plane, and torsion interactions are called bonded interactions because the atoms involved must be directly bonded or bonded to a common atom. The van der Waals and electrostatic (qq) interactions are between non-bonded atoms [8-24].
Hartree-Fock
The Hartree-Fock self–consistent method [5-6,27- 32] is based on the one-electron approximation in which the motion of each electron in the effective field of all the other electrons is governed by a one-particle Schrodinger¨ equation. The Hartree- Fock approximation considers of the correlation arising due to the electrons of the same spin, however, the motion of the electrons of the opposite spin remains uncorrelated in this approximation. The methods beyond self-consistent field methods, which treat the phenomenon associated with the many-electron system properly, are known as the electron correlation methods. One of the approaches to electron correlation is the Møller-Plesset (MP) [5,6,57,58] perturbation theory in which the Hartree-Fock energy is improved by obtaining a perturbation expansion for the correlation energy [5]. However, MP calculations are not variational and can produce an energy value below the true energy [6]. The exchangecorrelation energy is expressed, at least formally, as a functional of the resulting electron density distribution, and the electronic states are solved for self-consistently as in the Hartree-Fock approximation [27-30]. A hybrid exchange-correlation functional is usually constructed as a linear combination of the Hartree-Fock exact exchange functional,and any number of exchange and correlation explicit density functional. The parameters determining the weight of each individual functional are typically specified by fitting the functional predictions to experimental or accurately calculated thermochemical data, although in the case of the “adiabatic connection functional” the weights can be set a priori [32]. Terms like “Hartree-Fock”, or “correlation energy” have specific meanings and are pervasive in the literature [59]. The vast literature associated with these methods suggests that the following is a plausible hierarchy:
The extremes of ‘best’, FCI, and ‘worst’, HF, are irrefutable, but the intermediate methods are less clear and depend on the type of chemical problem being addressed [4]. The use of HF in the case of FCI was due to the computational cost.
For calculations a cluster of six computer models was used: Prescott-256 Celeron © D processors [2], featuring double the L1 cache (16 KB) and L2 cache (256 KB), Socket 478 clock speeds of 2.13 GHz; Memory DDR2 PC4200 512MB; Hitachi HDS728080PLAT20 80 GB and CD-R. The dynamic was held in Molecular Mechanics Force Field (Mm+), Equation (1), after the quantum computation was optimized via Mm+ and then by RHF [5-6,27-32], in the TZV [33,34] sets basis. The molecular dynamics at algorithm Polak- Ribiere [60], conjugate gradient, at the termination condition: RMS gradient [61] of 0, 1kcal/A. mol or 405 maximum cycles in vacuum [6,41]. The first principles calculations have been performed to study the equilibrium configuration of C13H20BeLi2SeSi molecule using the Hyperchem 7.5 Evaluation [41], Mercury 3.8 a general molecular and electronic structure processing program [18], GaussView 5.0.8 [64] an advanced semantic chemical editor, visualization, and analysis platform and GAMESS is a computational chemistry software program and stands for General Atomic and Molecular Electronic Structure System [7] set of programs. The first principles approaches can be classified in the Restrict Hartree-Fock [5-6,27-32] approach.
Discussions
The Figure 2 shows the final stable structure of the Bioinorganic molecule obtained by an ab initio calculation with the method RHF [5-6,27-32], in several sets of basis such as: STO-3G [7,30,60,71,83,84, 85,86]; 3-21G [7,30,60,71,83,84,85,86]; 6-31G [7,30,60,71,83,84,85,86]; 6-31(d’) [7,30,60,71,83,84,85,86]; 6-31(d’,p’) [7,30,60,71,83,84,85,86]; 6-311G [7,30,60,71,83,84,85,86]; 6-311G(3df,3pd) [7,30,60,71,83, 84,85,86]; SV [81,82]; SDF [71,72]; SDD [71,72]; SDDAll [71,72]; TZV [81,82]; CC-pVDZ [66,67,68,69,70]; CC-pVTZ [66-70]; CEP- 31G [66-70]; CEP-121G [66-70]; LanL2DZ [71,78,79,80]; LanL2MB [71,78,79,80], starting from the molecular structure of (Figure 1) obtained through a molecular mechanical calculation, method Mm+ and Bio+ Charmm [8-24,26,65].
The molecular structure shown in Figure 2 of the bio-inorganic molecule C13H20BeLi2SeSi, is represented in structure in the form of the van der Walls radius [4,5,6]. As an example of analysis, the set of bases TZV [81,82]. with the charge distribution (Δδ) through it, whose charge variation is Δδ = 4.686 au of elemental charge. In green color the intensity of positive charge displacement. In red color the negative charge displacement intensity. Variable, therefore, of δ- = 2,343 a.u. negative charge, passing through the absence of charge displacement, represented in the absence of black - for the green color of δ+ = 2.343 a.u. positive charge. The electric dipole moment () total obtained was p = 5.5839 Debye, perpendicular to the main axis of the molecule, for sets basis TZV [81,82]. By the distribution of charge through the bio-inorganic molecule it is clear that the molecule has a polar-apolar-polar structure, with neutral charge distributed on its main axis, the carbonic chain. A strong positive charge displacement (cation) at the polar ends of the molecule, in the two lithium and silicon atoms, bound to the carbon atom with strong negative (anion). Therefore, there is a displacement of electrons from the two lithium and silicon atoms towards the carbon attached to them. At the other end of the cyclic chain, attached to it is the totally neutral Selenium atom, while the beryllium is extremely charged with positive charge (cationic), represented in green color. While the two carbon atoms of the cyclic chain connected to Beryllium, with negatively charged (anionic), represented in red color. It happened, therefore, a displacement of electrons of the Beryllium atom towards the Carbons connected to it. An analysis of the individual charge value of each atom of the molecule could be made, but here it was presented only according to (Figure 2), due to the objective being to determine the polarpolar- polar, the polar characteristic of the molecule, whose moment of dipole is practically perpendicular to the central axis of the molecule. In Figure 2 the dipole moment is visualized in all the base sets, being represented by an arrow in dark blue color, with their respective values in Debye. This also presents the orientation axes x, y and z and the distribution of electric charges through the molecule. Analyzing the charge distribution through the molecule.
In all the sets of bases used, the Silicon atom presents a strong positive charge, that is, cationic form, represented in green color, except for the LanL2MB base, which presents a strong negative charge displacement, represented in red color. The two Lithium atoms accompany the cationic tendency of Silicon, but with less intensity. The Carbon atom connected to the central chain, and to Silicon and the two Lithiums, presents a strong negative charge, that is, anionic form, represented in red color. There is, therefore, a shift of the electric charges of the silicon atom and of the two Lithiums towards the Carbon. This charge displacement is evident in all the base sets studied, except for the base STO-3G and LanL2MB, which present almost neutral charge for the said Carbon atom.
The backbone of the molecule, that is, its central axis which has a chain of seven aligned Carbon atoms, has a homogeneous charge distribution, with approximately neutral polarity, represented by the absence of color (black). This charge neutrality is observed in the set of bases: STO-3G; 6-31 (d ‘, p’); TZV; SDD; CEP-31G; CCcVDZ; SV and CEP-121G. In the set of bases: 3-21G; 6-31G; 6-31 (d ‘); 6-311G; SDF; LanL2DZ and LanL2MB, the central axis of the molecule has a small distribution of negative charge throughout its length, due to the negative charge displacement of Hydrogen atoms (seen slightly in blackish green, tending to black) connected to each of their respective Carbon atoms, whose charge is slightly negative (visualized in blackish red color, tending to black). At the other end of the molecule is the cyclic chain of six Carbon atoms. Which has only one double connection. The cyclic chain is attached to the Beryllium atom and to two Carbon atoms, symmetrical and central to the cyclic chain. The Selenium atom is connected to two carbon atoms of the cyclic chain, the first Carbon atom being connected to the central axis of the molecule and the second atoms in sequence, being opposed to the double bonded cyclic chain atoms. The Beryllium atom presents a strong positive charge, cationic character, visualized in green color, in the set of bases: 3-21G; 6-31G; 6-311G; 6-311G (3df, 3pd); SV and TZV. Beryllium presents almost totally neutral charge in the set of bases: 6-31 (d ‘); 6-31 (d, p ‘); CC-pVDZ; cc-pVTZ; CEP-31G and CEP-121G. And charge, slightly positive in another basis studied. The Selenium atom is visualized in Figure 2, as seen always behind the cyclic chain. This presents a neutral charge distribution in all basis studied, with the exception of CCpVTZ and LanL2MB. The Table 1 presents the Molecular parameters of the atoms of the molecule C13H20BeLi2SeSi seed, obtained through computer via ab initio calculation method RHF [5-6,27-32] in base 6-311G**(3df,3pd) [7,30,60,71,83,84,85], obtained using computer programs GAMESS [7]. end software [64], (Figure 1) the right. The distance between the atoms is measured in Ångstron, as well as the position of the atoms in the coordinate axes x, y and z. The angles formed, and the angles formed in the dihedral are given in degrees. In the Table 2 containing the electric dipole moments, in the directions of the coordinate axes axes x, y and z, given in Debye, are presented in all the sets of bases studied. The minimum and maximum charge distributed through the molecule and the variation of the charge (in a.u.) by the extension of the molecule (C13H20BeLi2SeSi). They are represented by the variation of the intensities of the green color (positive charge), through black (zero charge) and red (negative charge), evenly distributed according to the basic functions used in quantum calculations allowed by quantum chemistry. The largest distributed charge variation (Δδ) per molecule was calculated on the base set TZV, with Δδ = 4.686 a.u., and the lowest in the CC-pVTZ set, with Δδ = 0.680 a.u., (Table 2). The highest total electric dipole moment () was obtained using the CEP-31G method, with p = 6.0436 Debye, with Δδ = 1.860 a.u., and the lowest electric dipole moment in the STO-3G method, with p = 4.2492 Debye, with Δδ = 1.510 a.u.
Conclusion
Calculations obtained in the ab initio RHF method, on the set of bases used, indicate that the simulated molecule, C13H20BeLi2SeSi, is acceptable by quantum chemistry. Its structure has polarity at its ends, having the characteristic polar-apolar-polar. Even using a simple base set the polar-apolar-polar characteristic is predominant. From the set of bases used in the RHF, based on 6-311G (3df, 3pd), the Silicon atoms, the two Lithium, have a strong density of positive charge, cationic, from the displacement of charges of these atoms towards the atom which Carbon are connected, which consequently exhibits strong negative charge density, anionic. It is observed a cyclic displacement and constant electric charges originating from the sp orbitals of the Carbon atom, (Figure 2). At the other end of the molecule, a similar situation occurs. The Beryllium atom presents a high density of positive charge, cationic character, due to the displacement of the electronic cloud of that one towards the Carbon atoms that is connected. These Carbon atoms also receive a displacement of negative charges, originating from the two Carbon atoms that are linked in the cyclic chain, in covalent double bonds. Now presenting these latter a strong density of positive, cationic charges, such as Beryllium, leaving the anionic Beryllium bound Carbon. The Selenium atom has a small anionic character. Among all simulated base assemblies, 6-311G (3df, 3pd), is unique that exhibits the characteristic of the central chain, with a small density of negative charges, near the ends of the Carbons of this.
In the CC-pVTZ base set, the charge density in relation to 6-311G (3df, 3pd) is 50% lower, with characteristics like those shown in the Silicon and the two Lithium atoms. However, the central chain presents an anionic feature, for all its extension, originating from the displacement of charges of the Hydrogen atoms connected to them. At the other end of the cyclic chain, the Selenium atom presents high density of negative charges, anionic, as well as in the cyclic chain the Carbon atoms present anionic characteristics, with little intensity, distributed proportionally by these atoms, originating from the displacement of charges of the Hydrogens linked to these. Except for the Carbon atom, connected to the central axis of the molecule that is not bound to Hydrogens atoms. The structure of the Bio-inorganic seed molecule for a bio-membrane genesis that defies the current concepts of a protective mantle structure of a cell such as bio-membrane to date is promising, challenging. Leaving to the Biochemists their experimental synthesis. The quantum calculations must continue to obtain the structure of the bioinorganic bio-membrane. The following calculations, which are the computational simulation via Mm+, QM/MM, should indicate what type of structure should form. Structures of a liquid crystal such as a new membrane may occur, micelles.
https://lupinepublishers.com/chemistry-journal/pdf/AOICS.MS.ID.000167.pdf
https://lupinepublishers.com/chemistry-journal/fulltext/the-creation-of-c13h20beli2sesi.-the-proposal-of-a-bio-inorganic-molecule-using-ab-initio-methods-for-the-genesis-of-a-nano-membrane.ID.000167.php
For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishersgroup.com/
For more Open Access Journal on Chemistry articles Please Click Here:https://lupinepublishers.com/chemistry-journal/
To Know More About Open Access Publishers Please Click on Lupine Publishers
Follow on Twitter : https://twitter.com/lupine_online
Follow on Blogger : https://lupinepublishers.blogspot.com/
submitted by Lupinepublishers-OCS to u/Lupinepublishers-OCS [link] [comments]

conjugation chemistry meaning video

- YouTube Bacterial Conjugation - YouTube 5.8 Effect of Congugation on Wavelength of ... - YouTube Hyperconjugation Explained - YouTube conjugated systems - YouTube Stability of Conjugated Systems - YouTube What Is a Conjugate? - YouTube

Conjugation exists when three or more atoms with the ability to resonate are adjacent to each other (overlapping). Concept #1: Definition of Conjugation. Concept #1: Definition of Conjugation. play-rounded-fill. play-rounded-outline. play-sharp-fill. play-sharp-outline. pause-sharp-outline. pause-sharp-fill. What does conjugation mean? A conjugating or being conjugated; union. (noun) Dictionary ! Menu Conjugation meaning. kŏn'jə-gā'shən . Filters (chemistry) A system of delocalized orbitals consisting of alternating single bonds and double bonds. Bonds alternate in a chain so long as each atom has an available p-orbital. Conjugation tends to lower the energy of the molecule and increase its stability. Conjugation is common in conducting polymers, carbon nanotubules, graphene, and graphite. It's seen in many organic molecules. Conjugate Acid Definition. Conjugate acids and bases are Bronsted-Lowry acid and base pairs, determined by which species gains or loses a proton. When a base dissolves in water, the species that gains a hydrogen (proton) is the base's conjugate acid. Acid + Base → Conjugate Base + Conjugate Acid. The LibreTexts libraries are Powered by MindTouch ® and are supported by the Department of Education Open Textbook Pilot Project, the UC Davis Office of the Provost, the UC Davis Library, the California State University Affordable Learning Solutions Program, and Merlot. We also acknowledge previous National Science Foundation support under grant numbers 1246120, 1525057, and 1413739. Conjugation occurs when p orbital on three or more adjacent atoms can overlap Conjugation tends to stabilize molecules. Allylic carbocations are a common conjugated system. The positive charge of a carbocation is contained in a P orbital of a sp2 hybridized carbon. This allows for overlap with double bonds. The term conjugation has different meanings in chemistry; conjugation may refer to the joining of two compounds to form a single compound or it can be the overlap of p-orbitals across a σ bond (sigma bond). Since we are comparing conjugation with hyperconjugation, i.e., interaction of σ-bonds with a π network, in this article, we’ll consider the second definition of conjugation. Conjugation. The word "conjugation" is derived from a Latin word that means "to link together". In organic chemistry terms, it is used to describe the situation that occurs when π systems (e.g. double bonds) are "linked together". An "isolated" π (pi) system exists only between a single pair of adjacent atoms (e.g. C=C) Hi, The term “conjugation” is used with respect to both biochemistry and microbiology. In biochemistry, conjugations are the turning of substances into the hydrophilic state by the body. A typical conjugation reaction is basically the covalent att... ‘Glutathione conjugation is also the primary mechanism of eliminating electrophilic xenobiotics (some of which are carcinogens) in the liver.’ 2.3 Chemistry The sharing of electron density between nearby multiple bonds in a molecule.

conjugation chemistry meaning top

[index] [2263] [6222] [4606] [1444] [8907] [8671] [1539] [3631] [6317] [7103]

- YouTube

explanation of conjugated systems and example problems 12 Frontier Molecular Orbitals(Introduction to BMO,ABMO,HOMO,LUMO) https://www.youtube.com/watch?v=9fnWwB0blak&t=76s Here i have discussed about Highest occu... We use conjugates in the manipulation of imaginary and complex numbers. So it's important to understand what a conjugate is. This short video explains it. Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. https://Biology-Forums.com Ask questions here: https://Biology-Forums.com/index.php?board=3.0 Facebook: https://facebook.com/StudyForcePS/ Instagram: ht... More substituted carbocations tend to be more stable. Here, Professor Davis explains the role of hyperconjugation in the process of stabilizing this critica... Donate here: http://www.aklectures.com/donate.phpWebsite video link: http://www.aklectures.com/lecture/stability-of-conjugated-systemsFacebook link: https://...

conjugation chemistry meaning

Copyright © 2024 top100.realmoneybestgame.xyz